Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy

February 5, 2019

Dr. Mazen Hanna describes the findings of ATTR-ACT, a study aimed at the treatment of transthyretin (TTR) amyloid cardiomyopathy with the medication tafamadis. Those who were treated with the medication had reduced mortality, hospitalizations, and better functional capacity and quality of life.  This is an exciting new breakthrough for patients with TTR amyloidosis. 

Login to view comments. Click here to Login